Kiromic BioPharma, Inc. (KRBP)
| Market Cap | 57.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.20M |
| Shares Out | 4.51M |
| EPS (ttm) | -4.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $7.80 |
| Previous Close | $8.00 |
| Change ($) | -0.20 |
| Change (%) | -2.50% |
| Day's Open | 7.75 |
| Day's Range | 7.51 - 8.04 |
| Day's Volume | 1,746 |
| 52-Week Range | 7.51 - 18.50 |
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress
HOUSTON--(BUSINESS WIRE)---- $KRBP #KRBP--Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therape...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamon...
HOUSTON--(BUSINESS WIRE)--Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence (“A.I.”) platform to improve...
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (the “Company”), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeu...
About KRBP
Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Lon... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol KRBP |